SEC Form 4 · accession 0000886163-17-000044
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John L Higgins
Officer — Chief Executive Officer · Director
Period of report
Mar 20, 2017
Accepted (ET)
Mar 21, 2017 · 5:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Mar 20, 2017 | S | 4,000 | $109.10 | D | 139,171 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 22, 2016, in accordance with Rule 10b5-1.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.49 to $109.48, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.